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Treatment of children with cancer on clinical trials, often in the context of national and international co-
operative groups, is one of the cornerstones of pediatric oncology treatment and has been shown to
improve outcomes of children with cancer. While enrolling children with cancer in prospective multi-
centre trials has become the norm in high-income countries, it has remained an exception in low and
middle-income countries until recently. In this article, we brieﬂy review the global landscape of pediatric
oncology co-operative groups and then discuss the Indian scenario including more recent developments
of the formation and galvanization of the Indian Pediatric Oncology Group (InPOG). The mission of InPOG
is to improve the outcomes of children with cancer in India by collaborative research. A roadmap for the
development and conduct of an InPOG study has been created and 21 disease-speciﬁc subcommittees
have been formed. Multi-centre studies on Hodgkin lymphoma and acute lymphoblastic leukemia are
currently recruiting and several others are under development.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Management of children with cancer offers one of the most
striking examples of progress in modern medicine. In the 1950s,
less than 10 percent of children with cancer were cured. Today,
nearly 80 percent will survive the disease [1,2]. Many factors can be
attributed for this progress: multimodality treatment, combination
chemotherapy, improved drugs, risk stratiﬁcation and supportive
care. Underpinning all these has been the early incorporation of
research and multi-centre clinical trials often in the context of
national (and increasingly international) co-operative groups
[3e6]. Such an approach, which is one of the cornerstones of pe-
diatric oncology treatment, has been shown to improve outcomes
of childrenwith cancer [6e8] and is the accepted form of delivering
treatment in the 21st century [4,9].
Collaboration in treating children with cancer is a necessity as it
is a relatively rare disease. This allows for pooling of data, com-
parison of results, and ultimately, improved outcomes. By system-
atically testing novel agents and treatment combinations/schedulesncology, Dr. B. R. A. Institute
Sciences, New Delhi, 110029,
).
atology Oncology Chapter of
apter of Indian Academy of Pediatr
enses/by-nc-nd/4.0/).in comparison with alternate protocols (often ina randomized
fashion), the studies from cooperative groups have helped deter-
mine the most effective agent or treatment strategy which is then
incorporated into successive clinical trials. Moreover, the multi-
disciplinary nature of these groups brings together professionals
from diverse backgrounds and different expertise, hence allowing
for exchange of ideas, discussion and innovation.
In this article, we brieﬂy review the global landscape of pediatric
oncology co-operative groups and then discuss the Indian scenario
including more recent developments of the formation and galva-
nization of the Indian Pediatric Oncology Group (InPOG).1. Evolution of global pediatric oncology co-operative groups
and collaborative research
The origins of pediatric oncology co-operative groups can be
traced back to 1955 with the formation of the Cancer and Leukemia
Group B Cooperative Group as well as the Acute Leukemia
Chemotherapy Cooperative Study Group A (forerunner of the
Children's Cancer Group), both in USA [4,10]. Published in 1960, the
comparison of 6-mercaptopurine versus the combination of 6-
mercaptopurine and azaserine in the treatment of acute leukemia
in children, is regarded as the ﬁrst multi-centre co-operative clin-
ical trial in childhood cancer [11]. Over the next two decades, otherics. Production and hosting by Elsevier B.V. This is an open access article under the
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Study Group (forerunner of the Pediatric Oncology Group), National
Wilms Tumor Study Group, and Intergroup Rhabdomyosarcoma
Study Group were established in USA [4,10]. All these groups con-
ducted landmark multi-centre prospective clinical trials allowing
for signiﬁcant advancements in the outlook of children with cancer
[10]. In the year 2000, they all merged into a single cooperative
group - the Children's Oncology Group (COG) in order to combine
efforts, accelerate progress and share resources. With over 5000
members from 240 pediatric cancer centers located in seven
countries (Australia, Canada, Mexico, Netherlands, New Zealand,
Switzerland, USA) more children with cancer have been treated by
COG than by any other group [4,10]. Recently COG has brought out a
series of publications which serve as a ﬁve year blueprint for
research within the organization [12].
Emulating the practice from USA, similar co-operative groups
were formed mainly in Europe and some other high-income
countries(HIC) like Japan. The earliest and most notable among
these groups were the United Kingdom Children's Cancer Study
Group (forerunner of the Children's Cancer and Leukaemia Group)
and the various working groups in Germany for leukemias
(including BFM which represented centres in Berlin, Frankfurt and
Munster) and solid tumorsnow fused under the Society for Paedi-
atric Oncology/Haematology representing Germany and Austria
[13,14]. 70e90% of children with cancer in these countries are
enrolled on clinical trials [13,14]. Despite formation of national co-
operative groups, the rarity of several childhood cancers like me-
dulloblastomas [15], Hodgkin lymphomas [16], neuroblastomas
[17], Wilms tumour [18], liver tumours [19] and sarcomas [20,21],
has necessitated collaborations in Europe (several under the um-
brella of International Society of Pediatric Oncology) with clinical
trials which have transcended geographical boundaries. For clinical
trials on certain childhood cancers like osteosarcoma and B-cell
non-Hodgkin lymphoma there have even been transatlantic col-
laborations between COG and European institutions [22,23].
While enrolling childrenwith cancer in prospectivemulti-centre
trials has become the norm in HIC, it has remained an exception in
low andmiddle-income countries (LMIC) until recently. The clinical
trials conducted by the Brazilian Pediatric Oncology Group is an
example of such exception, although only a minority of children
with cancer in Brazil get enrolled on their clinical trials [24]. In such
a backdrop at the start of the 21st century, multi-centre, multina-
tional collaborative efforts have sprouted in LMIC with Central
America and Africa leading the way. The Asociacion de Hemato-
Oncología Pediatrica de Centro America(established 1998) is a
consortium of seven Central American countries (Guatemala,
Honduras, El Salvador, Nicaragua, Costa Rica, Panama, Dominican
Republic)supported by several institutions in North America and
Europe [25]. An area of focus has been the development of shared
clinical protocols which now exist for most childhood cancers [25],
and results based on the prospective use of some of these have been
published [26e28]. Another example has been the Franco-African
Childhood Cancer Group, established in 2000, which currently in-
cludes 15 countries in francophone Africa supported by institutions
in France [29]. They have published prospected muti-centre studies
on Burkitt lymphoma and Wilmstumour [30e32] with collabora-
tive work ongoing on acute lymphoblastic leukemia, Hodgkin
lymphoma and retinoblastoma [29]. The latest entry into these
path-breaking collaborations in LMIC has been the Collaborative
WilmsTumour Africa Project, an initiative by colleagues from 8 in-
stitutions in 5 countries in Sub-Saharan Africa (Cameroon, Ethiopia,
Ghana, Malawi, Uganda) which are among the poorest in the world
[33]. Another exciting development has been the recentcollaboration in the ﬁeld of pediatric and adolescent germ cell tu-
mors between several institutes in HIC and institutes from Brazil,
Egypt and India [34].
2. The history of collaborative efforts in pediatric oncology in
India
Dedicated pediatric oncology units ﬁrst started to appear in
India in the early 1980s and were conﬁned to major metropolitan
centres. The Pediatric Hematology and Oncology (PHO) chapter of
Indian Academy of Pediatrics (IAP) was established in 1987 [35].
With a focus on building capacity and quality by training, it
embarked upon organizing conferences and workshops, along with
initiating fellowship programs including the pediatric hematology
oncology fellowship by the National Board of Exams. A key initia-
tive was the Indian National Training Project in Practical Pediatric
Oncology organized to train pediatricians, pediatric surgeons, and
postgraduates in the early recognition of childhood malignancies
and to prepare them for ‘shared’ care of these children [35]. There
was no collaborative research or clinical trials conducted during
this period under the aegis of PHO IAP.
The earliest report of collaboration in the ﬁeld of pediatric
oncology in India was that between Cancer Institute, Chennai and
the National Cancer Institute, USA in the early 1980s. Adopting a
more intense protocol (MCP841) than that being used at the time,
led to an improvement in the event free survival of acute
lymphoblastic leukemia from 20% to 40% [36]. This treatment
strategy was then adopted by Tata Memorial Hospital, Mumbai in
1986 and All India Institute of Medical Sciences, New Delhi in 1992
[37]. With this common protocol, event free survival rates of
40e60% were achieved and result of this landmark collaboration,
remains the only published prospectivemulti-centre interventional
study related to childhood cancer from India till date [37].
As we entered the 21st century, the scientiﬁc output of the In-
dian pediatric oncology community began to surge in the form of
scientiﬁc presentations and publications [38,39]. However, these
were of relatively low scientiﬁc quality and there was a glaring
absence of multicenter studies [38,39]. Around the same time, but
distinct from these “scientiﬁc” efforts, philanthropic initiatives
partnering with treatment centres became increasingly prevalent
in India. These not only supported the medical treatment, but also
provided more holistic support with nutritionists, nurses, social
workers, logistics, data managers, etc. The most recognizable
among these were JivDaya Foundation and Cankids … Kidscan,
both of whom had a national footprint [40]. Although even here,
collaborative research or clinical trials was not an area of focus,
their efforts brought individuals from across India together and the
additional resources like databases, data managers, nurses, etc.
made the start of collaborative research more viable.
3. Indian Pediatric Oncology Group (InPOG)
The need to establish a national cooperative group in order to
develop prospective multi-centre clinical trials in India became
increasingly apparent. Such a strategy was critical to understand
the biological differences in the disease, to assess responses to
treatment and ultimately to improve childhood cancer survival in
India. With this goal in mind, some members of the PHO IAP led by
Dr Bharat Agarwal, Dr Purna Kurkure and Dr Anupam Sachdeva
formed InPOG in 2008 [41]. The mission of InPOG is to improve the
outcomes of childrenwith cancer in India by collaborative research.
The focus during the early years of InPOG was to put the systems in
place to allow the running of such a group.
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mission. All members of PHO IAP who had an interest in research
were invited to join InPOG and asked to specify their areas of in-
terest. This information was used to create 21 subcommittees and
populate the members of each along with nomination of the chair
(Table 1). The role of each InPOG subcommittee is to.
 Develop broad goals and speciﬁc objectives for the respective
subcommittee
 Initiate and promote multicenter clinical trials and other
research in their ﬁeld
 Identify a panel of Indian and international reviewers relevant to
their ﬁeld
A roadmap for the development and conduct of an InPOG study
has been created (Fig. 1). This deﬁnes the roles of the primary
investigator, the reviewers, the InPOG subcommittees and the
InPOG executive along with the desired timelines to execute some
of the actions on the roadmap. A key recommendation is that a
minimum 5 centers have to participate in a collaborative study to
be eligible to be considered as an InPOG study. The current portfolio
of InPOG studies in displayed in Table 2. This includes two currently
recruiting studies on Hodgkin lymphoma and acute lymphoblastic
leukemia as well as several others, which have been granted pro-
visional InPOG registration and are under development.
Currently there are 109 members of InPOG from 55 institutes in
India of which the majority (70%) are pediatric hematologists/on-
cologists. These members work in hospitals in the private sector
(48%), the public sector (43%) and others (9%), and half of themTable 1
InPOG disease subcommittees and chairs.
Subcommittee Chair
Acute lymphoblastic leukemia Prof Vaskar Saha
Acute myeloid leukemia Dr Sameer Bakhshi
Hodgkin lymphoma Dr Jagdish Chandra
Non-hodgkin lymphoma Dr Amita Trehan
Chronic myeloproliferative disorders Dr Deepak Bansal
Central nervous system tumours Dr Girish Chinnaswamy
Renal tumours Dr Sandeep Agarwala
Neuroblastoma and other SNSTumours Dr Satya Yadav
Liver tumours Dr Priyakumari T
Retinoblastoma Dr Ashwin Mallipatna
Soft tissue sarcoma Dr Siddharth Laskar
Ewing sarcoma and PNET Dr Bivas Biswas
Osteosarcoma Dr Tushar Vora
Germ cell tumours Dr VenkatRadhakrishnan
Histiocytosis Dr GauravNarula
Epithelial & rare tumours Dr Maya Prasad
Hematopoietic stem cell transplantation Dr Sunil Bhat
Supportive care Dr Brijesh Arora
Access to care Ms Shalini Jatia
Epidemiology Dr Ramandeep Arora
Late effects Dr Gauri Kapoor
PNET e primitive neuroectoderal tumour, SNS e sympathetic nervous system.work in centres where >100 newly diagnosed childhood cancer
patients are treated every year. 48% of InPOG members have more
than 10 years experience working with children with cancer and
57% have more than 10 peer-reviewed publications.
New collaborative endeavors like InPOG bring with them their
own challenges, particularly in the early formative years. This is
especially relevant in the Indian context where there is signiﬁcant
heterogeneity among treating centres with regard to annual patient
caseload as well as the ﬁnancial model of service delivery. More-
over, there have been no previous standards set or guidelines is-
sued as to what constitutes a treatment centre, neither is there any
regulation to enforce this. While this is desirable and would
improve the quality of treatment (and research), undertaking any
activities in this direction are outside the scope of InPOG. Other
challenges relate to administrative, regulatory and procedural is-
sues. These include, acquiring funds, developing standard oper-
ating procedures, understanding regulatory barriers, developing
clinical trail management systems and promoting research gover-
nance. Members of the InPOG executive are tasked with addressing
these and steady progress is being made.
Further issues include lack of trained manpower, in this case,
clinicians with training and experience in multi-centre clinical
trials as well as an absence of a pool of statisticians and other
research staff which would form the bedrock of developing these
clinical trials and taking them to fruition. An important devel-
opment has been the increasing number of trained pediatric
oncologists from Indian institutes as well as those emigrating
from outside India who now form the critical human resource
needed for such a collaborative group to succeed and harnessingAfﬁliations Contact email address
Tata Medical Center, Kolkata vaskar.saha@tmckolkata.com
Dr. BRA Institute Rotary Cancer
Hospital, All India Institute of Medical
Sciences, New Delhi
sambakh@hotmail.com
Lady Hardinge medical College,
Kalawati Saran Children's Hospital, New
Delhi
jchandra55@gmail.com
Postgraduate Institute of Medical
Education & Research, Chandigarh
trehanamita@hotmail.com
Postgraduate Institute of Medical
Education & Research, Chandigarh
deepakbansaldr@gmail.com
Tata Memorial Hospital, Mumbai girish.c.tmh@gmail.com
All India Institute of Medical Sciences,
New Delhi
sandpagr@hotmail.com
Medanta e The Medicity Hospital,
Gurgaon
satya_1026@hotmail.com
Regional Cancer Centre, Trivandrum drpriyarcc@gmail.com
NarayanaNethralaya, Bangalore ashwinmc@gmail.com
Tata Memorial Hospital, Mumbai laskars2000@yahoo.com
Dr. BRA Institute Rotary Cancer
Hospital, All India Institute of Medical
Sciences, New Delhi
bivasbiswas@gmail.com
Tata Memorial Hospital, Mumbai tusharsvora@yahoo.com
Cancer Institute, Chennai venkymd@gmail.com
Tata Memorial Hospital, Mumbai drgauravnarula@gmail.com
Tata Memorial Hospital, Mumbai maya.prasad@gmail.com
Mazumdar Shaw Cancer Center,
Narayana Health City, Bangalore
sunilbhat_9@hotmail.com
Tata Memorial Hospital, Mumbai brijesh.aurora@gmail.com
Tata Memorial Hospital, Mumbai shalinijatia@hotmail.com
Max Super Speciality Hospital, New
Delhi
childhoodcancer@gmail.com




Current portfolio of InPOG studies.
InPOG number Study title
Ongoing InPOG studies
InPOG-HL-15-01 A collaborative study for newly diagnosed
childhood Hodgkin's lymphoma patients in
India
InPOG-ALL-15-01 An Indian Childhood Collaborative Leukemia
Group multicentre national standardization
study for newly diagnosed acute lymphoblastic
leukemia
InPOG studies in development with provisional registration
InPOG-SUPP-15-01 (P) A Prospective Open-labeled Randomized
Control Trial of Proactive Enteral Nutrition
Versus Standard of Care in Children with Cancer
and High Nutritional Risk
InPOG-LE-15-01 (P) The Indian Childhood Cancer Survivorship
Study (C2S study): After treatment completion
registry of childhood cancers e Phase 1
InPOG-ACC-15-01 (P) Multi-site Prospective Study to Determine
Household Out-of-Pocket Expenditure Incurred
by Families of Children Newly Diagnosed with
Cancer in India (HOPE Study).
InPOG NHL-15-01 (P) A Retrospective Multicentric Study of
Contemporary Epidemiology & Outcome of
Childhood B-NHL in India
Fig. 1. Roadmap of developing and registering an InPOG study.
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this. Perhaps, the greatest challenge to transforming the land-
scape of pediatric oncology research in India lies in overcoming
inertia to collaborate, transforming long-held views of skepti-
cism and generating self-belief. Providing leadership, being in-
clusive, and developing regular channels of communication, can
achieve this. Successful development and execution of the ﬁrst
few InPOG clinical trials would go a long way in bringing about
this change.
It is important to emphasize that InPOG is not and does not
intend to be a funding body. It is expected that the individual chief
investigators will be responsible for obtaining the necessary
funding for their respective studies. InPOG merely serves to bring
the researchers together and conduct research in an organized and
disciplined manner, and assist in developing multi-centric
contribution.4. The way ahead
These are but the ﬁrst steps of an exciting collaborative
journey ahead. The early signs look promising with great inter-
est among the pediatric oncology community, the allied spe-
cialists as well as other stakeholders like the parent support
groups. In the short term, the InPOG executive aims to facilitate
the optimum functioning of each disease subcommittee, secure
support and funding for a common clinical trial management
system which could be used by any InPOG study, and develop a
manuscript monitoring committee. Funding sources being
explored include the government, philanthropic organisations
as well as the pharmaceutical industry. A dedicated section on
the PHO IAP webpage (www.phoindia.org) is also being planned.
Ultimately the success of this endeavor would be measured by
the progress it makes in improve the outcomes of children with
cancer in India.Conﬂict of interest statement
The authors declare that they have no conﬂict of interest.Primary investigator Salient features
Jagdish Chandra Recruitment Commenced e Aug 2015
Centres recruiting e 18
Patients recruited e 61 (target 350)
Expected duration of recruitment e 3 years
Vaskar Saha Recruitment Commenced e Feb 2016
Centres recruiting e 7
Patients recruited e 0 (target 2240)
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